August 3, 2010 — A single intravenous dose of the N-methyl-D-aspartate (NMDA) antagonist ketamine hydrochloride produces a robust antidepressant effect within 40 minutes in patients with ...

I counsel individuals, couples and families, helping them to restore hope, find solutions and transform their lives. I have extensive experience working with trauma issues, from the little hurts and ...

I specialize in the assessment and treatment of depression, anxiety, borderline personality and adjustment disorders. Difficulty managing intense emotions, inability to cope with distress, and ...

For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...

Despite missing the primary endpoint, the novel K V 7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.